Metastasis is a life-threatening disease that accounts for as much as 90% of cancer-related mortality. Carcinoma cells have often spread to distant organs at the time patients present with cancer. Routine clinical examinations have produced significant progress in detecting metastasis but existing methods for screening cancer patients are incapable of detecting micrometastasis and disseminated tumour cells (DTCs) in distant organs. Adjuvant chemotherapy and adjuvant radiotherapy are anticipated to prevent relapse and death. However, over periods of time ranging from years to decades, these metastatic cells residing in distant organs often relapse, corrupt the local microenvironment and acquire the ability to develop into macrometastases. Metastatic nodules are known to be formed by carcinoma cells harboring increased numbers of epi/genetic alterations conferring aggressive and drug-resistant propensities. In addition, more recently emerging evidence supports the notion that the tumour-associated stroma, consisting of endothelial cells, leukocytes, macrophages, myofibroblasts, bone marrow-derived progenitors and abundant extracellular matrix (ECM), significantly facilitates tumour metastasis. The molecular signalling underlying the complexity of heterogeneous stromal-tumour interactions that is relevant to tumour metastasis is the subject of intensive research. The tumour-associated stroma, in addition to tumour cell-autonomous alterations plays significant roles to instigate and support progression of the multi-step processes of tumour metastasis.
The invasion-metastasis cascade
It has been widely accepted that carcinoma cells disseminate into distant organs via blood or lymphatic vessels. Recent studies support that the blood circulation plays clearly pivotal roles in metastatic dissemination 1) . The contribution of the lymphatic vessels to the dispersion of cancer cells is, however, considered to be less obvious. It is documented that functional lymphatic vessels are rarely found through tumour masses due to their little internal lydrostatic pressure resulting in their collapse.
The depiction of the invasion-metastasis cascade ascribes several distinct steps to the overall process, as shown in Figure-1 . The initial step of localised invasiveness enables in situ carcinoma cells to breach the basement membrane followed by their intravasation into either lymphatic or blood microvessels. The latter may then transport these cancer cells to distant anatomical sites, where they may be trapped and subsequently extravasate and form dormant micrometastases. Eventually some of the micrometastases may acquire the ability to colonise the tissue in which they have landed, enabling them to form a macroscopic metastasis. The last step so-called colonisation seems to be the most inefficient of all 1) . The small probability of completing all steps of this cascade supports the notion that any single cancer cell leaving a primary will rarely succeed in becoming the founder of a distant, macroscopic metastasis. In spite of the fact that recent studies extensively investigated tumour metastasis at molecular levels, a number of questions still remain unanswered. For example, it is unclear whether the multi-step processes of metastasis including colonisation are mediated by one or other distinct signalling pathways and whether the metastasis-promoting signal pathway differs from the primary tumourpromoting signal pathway. Notably, the tumourassociated stroma is also assumed to promote metastasis by influencing each step of the invasion-metastasis cascade ( Figure-1 ). Studying the tumour-stroma interaction during progression and dissemination of carcinoma cells would therefore be crucial for understanding the biology of tumour metastasis that allows the development of novel diagnostic and therapeutic approaches.
Spread of distinct cancer cell populations and evolution of metastasis
Cellular origins of carcinoma cells in a primary tumour have been extensively studied for the past three decades, however, those of DTCs begin to be investigated very recently. The long standing question is whether metastasis is formed by cancer cells that were present at the late or early stage of primary tumours. Figure-2 shows two existing models supporting"late dissemination"or"early dissemination"that allows stepwise progression or parallel progression of DTCs, respectively, during the series of tumourigenesis 2) . It has been believed that dominant or minor clones present in the late stage of tumours could give rise to metastasis ( Figure-2 ). In contrast, carcinoma cells disseminated during relatively early tumourigenesis, are also indicated to form metastasis 3) .
Genetic alterations harboured by carcinoma cells have long been considered to play major roles in promoting the invasion-metastasis cascade. Recent studies using whole genome sequencing and copy number analyses examined genetic alterations in detail in carcinomas, including those of the colon, pancreas, breast and prostate. For these studies, matched pairs of primary tumours and metastases were employed. Considerable sharing of somatic mutations identified in metastases with those found in the corresponding primary tumours was revealed in several cases. It was concluded that (4) formation of micro and/or macroscopic metastases in distant organs (colonisation). The ability of distinct carcinoma cells to metastasise into distant organs depends on their cellular origins and the epi/genetic alterations acquired and accumulated by these cells during the course of tumour progression. In addition, tumour-associated stroma also plays pivotal roles to influence the invasion-metastasis cascade. metastases had originated from predominant populations of primary carcinoma cells harboring alterations late in the genetic evolution of carcinomas. This conclusion supporting a stepwise progression model of carcinoma metastasis contradicts a parallel progression model (Figure-2) . The latter proposes that carcinoma cells, which disseminate to distant organs early during tumour progression, may acquire genetic alterations independently of those present in primary tumour cells. In recent years, it has been shown that tumour cell dissemination is often an early event, suggesting that primary and metastatic sites evolve in parallel and independently 3) . These two events-stepwise and parallel progression models-would not be mutually exclusive and the both may occasionally occur during the series of tumour progression. Molecular and biological characteristics of tumour cells metastasised should therefore be assessed in each patient based on the comparison with those in cancer cells in primary tumour, in order to develop individually the most suitable therapeutic approaches against the metastatic recurrence.
Metastasis-promoting signal from the tumour-associated stroma
Various types of non-neoplastic stromal cells are frequently present within human primary carcinomas, including heterogeneous populations of immune cells, endothelial cells, fibroblasts, myofibroblasts and bone marrow-derived progenitors ( Figure- Tumour-associated macrophages (TAMs), which are mature myeloid cells, can be found within the tumour microenvironment in high numbers. TAMs, when educated by microenvironmental cues within the primary tumour, adopt the M2/trophic phenotype. M2 type TAMs produce paracrine factors promoting neo-angiogenesis, immunosuppression and local inflammation, all of which facilitate the invasion-metastasis cascade. For example, IL-4 and colony-stimulating factor-1 (CSF-1) cytokines produced by carcinoma cells and/or T-lymphocytes stimulate recruitment and activation of TAMs, which promote cancer cell invasion by producing epidermal growth factor (EGF) and cathepsin B and S proteinases (Figure-3). TAMs also play essential roles in promoting colonisation of DTCs in distant organs. Prior to their extravasation, carcinoma cells which enter the circulation need to overcome anchorage-independent growth conditions, i. e., survive sheer forces Breast cancer cells secrete colony-stimulating factor-1 (CSF-1), a hematopoietic growth factor recruiting tumour-associated macrophages (TAMs) into the primary tumour. Infiltrating perivascular TAMs secrete epidermal growth factor (EGF) which chemotactically attracts cancer cells toward the vasculature and thereby facilitates their intravasation. In addition, IL-4 produced by breast cancer cells and CD4 + T lymphocytes boosts expression of EGF and cathepsin (Cts) B and S proteases by TAMs and further promotes TAM-instigated cancer cell invasion. In addition to the aforementioned factors TAM-derived CCL18 has also been shown to promote invasion of breast carcinoma cells via signalling through its cognate receptor, PITPNM3, whereas TAM-secreted protein acidic and rich in cysteine (SPARC) induces cancer cell migration by acting through αvβ5 integrin. CCR1 + CD34 + immature myeloid cells respond to CCL9 chemokine secreted from colorectal carcinoma cells, and infiltrate the invasive front of the tumour epithelium, where they produce metalloproteinases (MMPs) 2 and 9. CXCL5, another chemokine produced by breast cancer cells, attracts a different population of immunosuppressive myeloid cells (Gr-1 + CD11b + )
toward the invasive front of tumour tissues where they produce MMP2, 13 and 14 facilitating invasion and metastasis of cancer cells. Similarly, CCL5 chemokine secreted by mesenchymal stem cells (MSCs) enhances invasion and metastasis of breast carcinoma cells by activating the CCR5 receptors on these cells. Caveolin-1 (Cav1) expressed on carcinoma-associated fibroblasts (CAFs) facilitates tumour invasion through the force-dependent architectural regulation of extracellular matrix (ECM), including its stiffening. The primary tumour microenvironment is a source of abundant TGF-β which induces transient activation of TGF-β signalling in breast carcinoma cells promoting their motility and intravasation. In addition, stromal-derived TGF-β stimulates expression of angiopoietin-like 4 (ANGPTL4) by breast cancer cells；ANGPTL4 primes cancer cells to dissociate cell-cell junctions between vascular endothelial cells and thereby increases the levels of their extravasation. Notch ligands, DLL4 and/or Jagged1 (Jag1), expressed by tumour-associated endothelial cells (EC), macrophages and fibroblasts have been shown to mediate Notch signalling-dependent invasion of colon cancer cells. Activation of NFκB signalling in CAFs mediated by IL-1β secreted from infiltrating immune cells results in the production of pro-inflammatory chemokines (e.g., CXCL1 and CXCL2) which chemotactically recruit TAMs in the primary tumour, whereas CCL5 secreted by CAFs signals via the CCR1 receptor expressed on regulatory T cells (T-reg). The recruited T-reg can express RANKL, a ligand for the RANK receptor on the surfaces of breast cancer cells. Signalling mediated upon activation of RANK resulting in IKKα and thus NFκB activation allows cancer cells to evade apoptosis and facilitates their extravasation. Platelet-derived TGF-β induces the TGF-β-Smad2/3 signalling in cancer cells, whereas direct physical contact between platelets and tumour cells results in activation of the NFκB pathway. Activation of both forms of signalling leads to induction of the EMT phenotype in CTCs that increases their extravasation. hCLCA2, a Ca 2+ -sensitive chloride channel protein which is expressed by ECs, is implicated in directing β4-integrin-dependent adhesion between these cells and breast carcinoma cells, allowing the latter to undergo extravasation effectively. Vascular endothelial growth factor (VEGF) secreted by tumour cells also aids tumour cell extravasation via induction of Src signalling in ECs and the resulting disruption of the integrity of the EC barrier/layer. and resist anoikis. The subsequent colonisation is thought to be a rate-limiting step of metastasis, as it has been estimated that less than 0.01％ of circulating tumour cells (CTCs) which survive in the circulation, extravasate and give rise to micrometastases. The presence of large numbers of stromal cells, and the high density and stiffness of ECM are characteristic features of the tumour stroma, which is often referred to as a"desmoplastic"stroma. . For example, CAFs activated by infiltrating immune cells produce proinflammatory chemokines (e. g., CXCL1 and CXCL2) which mediate recruitment of TAMs into primary tumours, whereas the CCL5 chemokine secreted by CAFs recruits T-reg by signalling through the CCR1 receptor expressed on these cells. CCL5 secreted from mesenchymal stem cells (MSCs) (among CAFsʼ precursors), also acts through the CCR5 receptor (another receptor against CCL5 besides CCR1) expressed on breast carcinoma cells, thereby enhancing invasion and metastasis. Moreover, CXCL12 and fibroblast growth factor 2 (FGF-2) released by CAFs stimulate neoangiogenesis by recruiting endothelial progenitor cells and vascular endothelial cells, respectively.
Cancer stem cells (CSCs) and epithelial mesenchymal transition (EMT)
The cells of origin for metastasis are known to play major roles influencing the invasion-metastasis cascade. The concept of cancer stem cells (CSCs), whereby rare populations of carcinoma cells are capable of forming a tumour, derives from the well-established characteristics of normal tissue stem cells, including their self-renewal and multi-potency. Recent studies notably showed de novo induction of the stem cell state in various normal and carcinoma cells which underwent epithelial mesenchymal transition (EMT)
. The latter is a well-characterised process of cellular trans-differentiation through which epithelial cells acquire the mesenchymal phenotype. This trans-differentiation program is also reversible as judged by the cells undergoing mesenchymal-epithelial transition (MET). Furthermore, the bidrectional nature of the CSC phenotype (transition between CSCand non-CSC-states) was often observed as associated with the reversible EMT trait and this encouraged revision of the definition of CSCs in human breast carcinoma cells 6)-8)
. In addition to pro-invasive and anoikis-resistant propensities in cells undergoing EMT, the CSC trait was therefore highlighted as an additional trait of the EMTassociated phenotypes that are essential for the establishment of cancer metastasis.
A recent observation, however, conflicted with the notion supporting the EMT-induced CSC state. It was shown that an E-cadherin-expressing human prostate carcinoma epithelial cell line, which was originally isolated from liver metastasis experimentally generated in nudce mice, indeed exhibited stronger CSC and increased metastatic traits, compared to those in their mesenchymal counterpart 9) . Moreover, overexpression of Snail, an EMT transcription factor, induced mesenchymal phenotypes and suppressed their epithelial trait in these cells, although their CSC state and metastatic potential were significantly inhibited in the resulting Snail-expressing mesenchymal cancer cells. These findings therefore indicate the association of CSC state and mesenchymal trait may depend on the cellular context. Further investigation requires for clarifying how the EMT program influences CSC state promoting metastatic potential also in the different cellular context.
CTCs, DTCs and metastasis
CTCs found in the bloodstream, and DTCs that have already spread and localised in distant organs, are believed to be precursors of metastatic nodules. Importantly, increased CTC numbers and the presence of DTCs in bone marrow predict a poor outcome in breast cancer patients, indicating that these cells can serve as an independent prognostic factor for this disease. Notably, particular genetic alterations harboured in CTCs, which are responsible for drug-resistance, such as those of the epidermal growth factor receptor (EGFR) gene, have been detected in non-small-cell lung cancer patients. This may serve as a new approach for monitoring the genetic changes which develop de novo in carcinoma cells during application of systemic therapy.
A newly emerging hypothesis suggests that CTCs that are capable of giving rise to distant metastases are enriched for CSCs, and as such show increased invasiveness, anoikis-resistance, tumourinitiating potential and the ability to avoid cellular dormancy during metastatic colonisation. Indeed, it has been demonstrated that several CSC-enriched cancer cell populations show increased ability to form metastases when implanted intravenously into recipient mice. It is however unknown whether the emergence of spontaneous metastases observed in cancer patients is mediated by CTCs enriched for CSCs. Technical challenges of existing methods for handling and culturing CTCs make proving this assumption experimentally difficult. Low numbers of CTCs present in circulating blood, their short half-life and a paucity of functional markers available for their identification, render isolating CTCs very challenging. Interestingly, it has been shown that distinct populations of CTCs can be found in blood samples of cancer patients, including those circulating as single cells which show a mesenchymal or ameboid-like appearance and those found in the circulation in the form of epithelial sheets, indicative of collective movement of a group of epithelial cells. Moreover, CTCs appear to contain clusters of heterogeneous cell populations composed of platelets, leukocytes and mesenchymal cells.
The half-life of CTCs in the circulation is short, i. e., measured in hours, which is partially related to their fast clearance from the circulation and/or apoptosis. To date, CTCs and DTCs extracted from either patients or mouse tumour models are incapable of efficiently forming metastases when introduced into recipient mice 10) . These cells may require niche support to exert their potential to initiate and develop metastasis. Cells of primary tumours are known to be capable of inducing both local and systemic changes in the microenvironment that prime and facilitate their metastatic spread and promote colonisation of distant organs. A variety of soluble factors secreted by tumour cells and supporting stromal cells contribute to increased vascular permeability and penetration of blood vessels by cancer cells, immune evasion, and vascular adhesion which allow cancer cells to intravasate, survive in the circulation and extravasate into sites of metastatic nodule formation. Support provided by a local, organ-specific metastatic niche is also thought to play a critical role in the abilities of DTCs to initiate and develop metastasis. Further improvements in the techniques allowing detailed characterisation of CTCs and DTCs with regard to their epi/genetic status and gene expression profiles is needed to advance our knowledge of the metastasis-forming ability and CSC phenotype of these cells in future studies.
Closing Remark
Carcinoma cells possess the ability to instigate changes in the surrounding stroma in both primary and metastatic sites, which upon activation stimulate local invasion, dissemination and metastatic colonization of tumour cells 11) . Various cell-autonomous alterations within carcinoma cells resulting in corruption of the stroma have increasingly reported. The tumour-associated stroma is also shown to support CSC-niche formation and retarded immune surveillance, both of which facilitate survival and growth of cancer cells within primary tumours and metastatic nodules. Exploration of the signalling which underpins the formation of the niche for CSCs suggests its dependence on complex interactions between tumour and stromal cells, and their functional cooperation with cell-autonomous alterations within carcinoma cells. The development of therapeutic interventions targeting stromal-tumour interactions is therefore crucial and combining novel approaches with conventional therapies should be considered for increasing the efficacy of these treatments 12) .
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